Get notified when HRMY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Event of Default (unchanged) — The company disclosed a prior nonfinancial covenant default under its term loan that was waived in May 2026.
Harmony Biosciences Q2 revenue jumps 30.3% to $261.3M; net income up 89.6% to $75.4M
Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read
Key Changes
-
high
Net product revenue rose 30.3% to $261.3M, driven by a 26.5% increase in units shipped and a 7% price increase, partially offset by higher rebates.
MD&A: Revenue verify on EDGAR → -
high
Cost of product sold as a percentage of revenue climbed to 24.2% from 19.0%, reflecting new royalties under the Novitium License Agreement.
MD&A: Margin verify on EDGAR → -
high
The company disclosed a prior event of default under its term loan related to a nonfinancial covenant, which was waived in May 2026.
MD&A: Debt verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.
Partner
Trade HRMY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify